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                                                          INTRODUCTION 
DM is a state of chronic hyperglycaemia producing complications like 
neuropathy,nephropathy and retinopathy.It is also a strong co factor in causing 
atherosclerotic disease and dyslipidemia. 
 
The microvascular and macrovascular complication prevalence is 46% and 64% 
respectively. Diabetes is the commonest cause of non traumatic lower extremity 
amputations. It has been reported that annually, about 1 to 4 percent of those with 
diabetes develop a foot ulcer. 
 
Invariably the diabetic foot ulcers are chronic ulcers that are resistant to heal 
because of multidrug resistant organism growth and microvascular 
complications.
1,2
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Recent advances in concept of wound healing and the factors and cell types 
involved in wound healing have opened a pathway for curing chronic ulcers. 
 
PDGF is one among the growth factors important in angiogenesis and regeneration 
that is used in treating chronic ulcers. PDGF are derived from platelets which 
contain alpha and beta granules. The rh-PDGF  is produced  by recombinant DNA 
process by inserting the human gene  for  the  B  chain  of  the Growth Factor  in   
the yeast saccharomyces cevisiae.
3 
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AIM OF THE STUDY 
1. To evaluate the efficacy of PDGF over saline dressing in healing of diabetic  
ulcers of the foot. 
 
2. To compare and analyze the distribution of Diabetic ulcers of the Foot        
with age, sex, location of the ulcer(plantar or dorsum). 
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REVIEW OF LITERATURE 
      HISTORICAL  
 
The first Mention of diabetes dates back in Egypt in 1500BC,where  
Hesy-Ra mentioned Diabetes and ways to prevent “passing of too much urine”. 
Later in Greek Aretaeus of Cappodocia gave the first medical description of 
diabetes, referred it to „the melting down of flesh and limbs into urine. The 
terminology “diabetes” refers to siphon and  “mellitus” as honey. 
 
Grant Banting and Herbert Best proved that diabetes in dogs is 
reversible by providing them a extract from the pancreatic islets of Langerhans 
from healthy dogs thereby confirming endocrine role of pancreas in 1921.The 
World Diabetes Day is observed every November 14 in view of Banting`s 
birthday.
4 
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In 1500 Bc  papyrus entails the use of honey in local wound application for healing 
as antiseptic,lint was used as a wound contraction agent and animal grease as a 
mechanical sealant.
5 
Maibach conducted studies on wound healing using saline dressings in 1960,and 
recommended superior wound healing as compared to other dressing techniques.6 
 
                                     The understanding of concepts of growth factors in wound  healing  
over the decade has brought new field of interest in their usage in chronic ulcers. 
Various studies conducted in vitro proved their efficacy in cell proliferation and 
angiogenesis and wound contraction.  
 
Recombinant technology made it possible to acquire adequate quantity of growth 
factors for human trials. Many such trials of growth factor use in chronic diabetic 
ulcers were conducted. PDGF is now approved   for topical treatment of diabetic 
neuropathic ulcers by US-FDA. 3 
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      HEALING,REGENERATION & REPAIR 
 Healing 
      “Body replacement of destroyed tissues by the living tissue” or “Integrated  
series of cellular & biochemical events which restores the functional integrity & 
regains the strength of injured tissue”.7 
 
Regeneration 
“It is a process of replacement of lost tissue by an identical type of fresh 
tissue”. There  is  proliferation  of  surrounding  undamaged  specialized  cells, 
Seen  in-  [1] Epidermis [2] Endothelium [3] Liver cells [4] Mucous 
membrane.
8 
 
Repair 
It is the replacement of  tissues by granulation maturing into a scar”. e.g. 
muscle & nervous tissue.
9 
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HEALING:  
Definition: 
“Body replacement of destroyed tissues by the living tissue” or 
“Integrated series of cellular & biochemical events which restores the 
functional integrity & regains the strength of injured tissue” 
 
Phases of Healing: 
Wound healing & repair are complex processes that involves dynamic series of 
events. 
[1] Coagulation 
[2] Inflammation 
[3] Fibroplasia, Angiogenesis, Proliferation & Granulation tissue 
formation.  
[4] Epithelization 
[5] Collagen Synthesis 
[6] Wound contraction / Tissue Remodeling / Scar Maturation.
9 
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  COAGULATION,INFLAMMATION : 
• Inflammation is the first process of wound healing and essentially consists of  
coagulation and neutrophil aggregation. 
• Helps in preventing blood loss, covering wound surface, & holding the 
wound edges together & thus contributing to the healing process. 
• Knighton  et  al  (1982)  &  Ross  (1980)  have  shown  equivocally  that  
fibrin  & platelets play an important role in initiating the wound healing.
10
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GRANULATION PHASE OF WOUND HEALING : 
 Phases  of  wound  healing under  this  phase  are :  Fibroplasia,    
Angiogenesis, Proliferation. 
 
 A granulation tissue  is a highly vascular tissue, containing largely of 
1. Fibroblasts [Proliferating fibroblasts + Products of Fibroblasts] 
2. Endothelial cells lining capillaries of newly sprouting blood vessels 
3. Macrophages 
4. Pleuripotent Pericytes 
 
Above all are embedded in a matrix consisting 
1. Fibronectin 
2. Proteoglycans rich in Hyaluronic acid & collagen [This collagen is at first      
mainly of Type-III, changing later to Type I]. 
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FUNCTIONS OF GRANULATION TISSUE :- 
1. Supports the growing & migrating epithelial cells –The connective tissue 
matrix of granulation  tissue  forms  nutritive  substrate,  over  which  
regenerating epidermis can migrate & is gradually replaced by scar tissue. 
 
2. Fill the gap of the  wound. 
Factors which play important role in Granulation tissue formation:
11 
 
1. Chemotactic factors 
2. Growth Factors 
3. Structural molecules 
4. Proteases  
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ANGIOGENESIS 
12,13
 
 
Vital part of proliferative phase of wound healing & 
repair. It is seen in 
•   Embryonic development phase 
•   During repair process (throughout life span of an organism) 
•   Under certain pathological conditions 
 
                  Without Angiogenesis, invasion of the wound bed by macrophages & 
fibroblasts would cease due to lack of oxygen & nutrients. 
 
In the initial stages, these vessels lack the basement membrane & have 
loose cellular junction & are fragile in nature. Due to this, on slightest touch, 
the vessels bleed profusely which is a characteristic feature of newly formed 
capillaries. The leakage facilitates the movement of cells & macromolecules 
into wound site. 
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Step-I :  Angiogenesis Initiation 
There is disruption of tunica adventitia of blood vessels by proteolysis 
allowing sprouts of capillary vessels which help in cell migration into the 
wound site. Angiogenic factors acts on capillary endothelial cells, which 
releases collagenase. This enzyme degrades the collagen of basement 
membrane. 
 
Step-II:Angiogenesis Amplification 
Fragmentation  of  the  collagen  of  basement  membrane,  permits  the  
migration  of endothelial cells into the peri-vascular spaces. 
 
Step-III: Vascular Proliferation 
Endothelial cells migrate into the peri-vascular spaces where they form buds, 
which are added by the proliferation of cells within & near parent vessel.  
 
Step-IV:Vascular Stabilization and Angiogenic Suppression 
       Maturation of endothelial cells & organization into capillary loops 
• Functional Capillary Loops: During dermal repair, these buds grow rapidly 
towards the free surface, where they branch at their tips & unite to form 
functional capillary loops. 
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•   Superficial  Capillary  Plexus  :  On  these  loops,  new  buds  develop,  
    so that,  a superficial capillary plexus rapidly forms in the granulation tissue. 
• Canalization : Proliferation & branching of cords of endothelial cells 
later become canalized to form growing capillary buds of healing wound. 
• Fusion :  Capillaries originating from opposite sides of the wound fuse & 
establish a complete circulation with in the wound. 
 
REMODELLING OF THE VASCULATURE: 
There is constant remodeling of the vasculature, which involves 
obliteration of many of the capillaries. 
As each capillary loop becomes functional, it brings nutrients & oxygen 
to nearby cells, enabling the fibroblasts to secrete materials for the matrix, 
through which macrophages & other cells can migrate further. 
                As the scar maturation proceeds, capillaries gradually regress & the red 
vascular rich wound tissue transforms into a white, relatively avascular cell 
poor scar.  
                 The above proliferative & migratory processes are repeated 
sequentially, until wound bed is filled with granulation tissue. 
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        MACROPHAGIA 14,15 
 
• It is a point at which protecting & clearing functions of inflammatory 
response are linked to starting of reparatory process 
Macrophagia is  defined as : 
[1] Migration of Monocytes [from blood] to tissue injury site 
[2] Conversion of monocyte to Macrophage after migration to tissue injury 
site. These are key cells in dermal repair 
 
• Wound  macrophages,  which  appear  subsequent  to  the  cells,  play  
pivotal  role  in healing by liberating various factors. 
 
Macrophages & angiogenesis16 
          It appears that macrophages promote angiogenesis by liberating Endothelial 
Growth Factor (EGF). 
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Phase of 
wound healing 
 
Sources of 
collagenase 
 
Role of collagenase 
 
In early part of 
wound healing 
 
Neutrophils 
 
Collagen of wound debris is broken down by 
collagenase & converted to breakdown products of 
collagen, which is then cleared by phagocytes, so, 
they assist in tissue debridement 
 
In  later  part  of 
wound healing 
 
Macrophages 
 
This enzyme controls the amount of new collagen 
deposition. 
 
 
 
 
 
 
Macrophages & Collagenase Enzymes :  Role of Collagenase 
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Macrophages & Collagen: 
Macrophages secrete lactate which stimulates collagen synthesis by fibroblasts. 
 
 
         Migration of Fibroblasts – Mechanism17,18,19 
 
 
Phases of 
inflammation 
inflammation 
 
Chemical  which  acts  as  chemotactic  agent  for  
fibroblasts  in  their migration : 
 
Initial 
 
By Fibrin – Fibronectin – Collagen Scaffold of wound 
base  
 
Later 
 
By  Soluble chemical factor from macrophages & 
Collagen peptide  
 
Collagenation Mechanism
20 : 
                    Tissue replacement by fibrosis and scar formation. The main 
component of scar tissue & newly laid connective tissue is collagen. It is 
suggested that , the repaired tissue may contain ≥50% collagen material, & 
hence this aspect of healing is referred to as collagenation. 
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Defects in collagenation can give rise to: 
1)Poor Healing. 
2)Contractures 
3)Hypertrophic Scar 
Therefore an understanding of underlying bio-chemical,synthetic and 
remodeling processes leading to the formation of collagen is essential for the 
rational approach to wound repair. Interruptions in the synthetic process and 
consequences of such interference can provide knowledge for the clinicians 
with powerful tool to control scar formation. Collagen synthesis by fibroblasts 
begins early in wound healing, by day 03 or 05 and continues for several 
weeks, depending on wound site. 
 
 
COLLAGEN  FIBERS  
Functions of collagen include :  
1.   Support to the tissues. 
2.   Provides structural framework to other types of tissues. 
3.   Acts as a medium where blood vessels & nerves are passing. 
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4.   Bring & keeps the wound edges together & provides tensile strength 
for holding together. This holding strength prevents the breakdown of 
tissue (organ) at the healed site. 
5.   Fill the gap caused by the tissue loss. 
 
•   Collagen is the most abundant [25% of total body protein]  
 
proteins of the connective tissue. 
 
Collagen is essentially a product of fibroblasts. 
 
 
• Collagen Deposition : Collagen that gets deposited into the extra-
cellular matrix of the healing wound has 4 successive phases of 
synthesis: 
1.   Bio-synthesis of Tropo-collagen 
2.   Fibril Formation 
3.   Collagen Maturation 
4.   Collagen Degradation. 
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Types of collagen.: 14 types of collagen can be discerned, of which the most 
well characterized are shown in following table. 
 
Type  of 
collagen 
 
                     CHAINS 
Characteristi cs  
Distribution 
 
 
 
I 
 
 
 
α 1 (I), 
 
 
 
α 2(I) 
  Bundles       of 
banded fibers with 
high tensile 
strength 
Skin (80%), Bone 
(90%),   Tendons, Most 
other organs 
 
II 
 
α 1 (II) 
   Thin     fibrils, 
Structural 
proteins 
Cartilage   (50%), 
Vitreous Humour 
 
III 
 
α 1 (III) 
   Thin     fibrils, 
Pliable 
Blood       vessels, 
Uterus,          Skin 
(10%) 
 
IV 
 
Α 1 
 
Α 2 
 
α 3 
α 4,α 5, 
α 6 (IV) 
Amorphous All         basement 
membranes 
 
 
V 
 
α 1 
[V, α 
2(V)] 
  
 
α3(V) 
 Amorphous, 
Fine fibrils 
2-5%                 of 
interstitial tissues, blood 
vessels, Interstitial tissues 
VI α 1 (VI) α 2 (VI) α3 (V)    
 
VII 
 
α 1 (VII) 
   Anchoring 
Filament 
Dermal-Epidermal 
Junction 
 
VIII 
 
α 1 
(VIII) 
 
Α 2 
(VIII) 
  Probably 
Amorphous 
Endothelium-Descement‟s 
Membrane 
 
IX 
 
α 1 (IX) 
 
α 2 (IX) 
α3 
(IX) 
 Probably Role 
in   maturation of 
cartilage 
Cartilage 
X α 1 (X)    
 
XI 
 
α 1 (XI) 
Α 2 
(XI), α 
2 (XI) 
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Collagen Degradation: 
 
     •The static balance of collagen in a wound depends on both collagen 
production and also its degradation. 
• It is achieved  by the enzyme - Metalloproteinases. 
 
       GROUND SUBSTANCE IN HEALING WOUND: 
 
• Connective tissue consists of cellular and non cellular component 
(matrix). Matrix is again composed of fibres and ground substance. 
• Definition: This is non-fibrous part of the matrix in which cells and 
fibres are embedded. 
• Consistency: Except in mineralized connective tissue, the ground 
substance is a viscous gel. 
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                                     Constituents of Ground Substance 
 
Water High proportion 
Mucopolysaccharides It  has  been  suggested  that  the  fibroblasts,  on  the  outer 
 
surface,  have  a  layer  of  mucopolysaccharides  
  whose   charge   and   orientation   determine   the 
aggregation and orientation of tropocollagens. 
Fibronectin Fibronectin is a glycoprotein with high molecular weight 
There are two types of Fibronectin (a) 
Cell surface Fibronectin  and (b) 
Plasma Fibronectin 
Functions: Fibronectin  of  connective  tissue  matrix  acts  as  
a  glue between different matrix components  and fibroblasts 
Chondronectin It is a specific adhesive between chondroblasts and type II 
 
Collagen 
Mucoproteins  
Glycoproteins  
Lamenin  
Entactin  
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WOUND CONTRACTION: 8 
• Definition: “Wound contraction is a process by which wound heals in a 
centripetal manner 
•   Wound contraction is one function of granulation tissue which is critical 
for repair. 
•   The events of wound healing from injury to fibroplasias, occurs in almost 
all wounds. 
Certain events like wound contraction occurs characteristically in 
excision dermal wound and epithelization occurs in wounds of surface 
lining epithelium. 
• In humans, the wound contraction is less because in most parts of the 
body the skin is somewhat firmly attached to subcutaneous tissue but it 
can occur in areas like back of neck and buttocks. 
•   Timing of Wound contraction: 
Wound  contraction  starts  from  about  3rd  or  4th  day  of  
wounding  and continues up to 15th or 16th day and stops thereafter, 
irrespective of whether the wound is totally closed or not. 
•   Rate of wound contraction: 
             The rate of wound contraction is about 0.6-0.75 mm/day . 
  Wound contraction is not materially affected by size or shape of the 
wound but perhaps by the length of the wound perimeter. 
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   Mechanism of wound contraction : 
                     The mechanism of wound contraction is disputable and debatable. 
Many theories like Pull theory, Push theory / Picture Frame theory etc have been 
proposed but none of them appears to be satisfactory. 
                      Wound contraction can be both beneficial or detrimental. Wound 
contraction can lead to distortion, disfigurement and impairment of function.  
 
    EPITHELIZATION 
 
•   Epithelization is a process of wound healing involving body surfaces. 
• Unlike   healing by fibroplasias where lost parenchymal cells are 
replaced by non- specific connective tissue, in epithelialization lost 
epithelial cells are replaced by epithelial cells only. It is an example of 
healing by regeneration. 
• Stages  of  epithelization:  The  whole  process  of  epithelization  thus  
includes  the following stages. 
1. Mobilization and loosening of basal cells from their dermal 
attachment. 
2. Migration or movement of cells to a position of cell deficit. 
3. Proliferation or replacement of cells to a position of cell deficit 
and 
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4. Differentiation or restoration of cellular function. 
Epithelization which depends on several factors like: 
1) Size of wound 
2) Location of wound 
3) Shape of wound 
4) Impairment of blood supply 
5) Pathological modification of wound. 
 
•   Healing by epithelization occurs in: 
1)  Dermal wounds, 
2)  Wounds of tracheobronchial surface, 
3)  Surface wounds in gut, urinary bladder, uterus etc. 
 
•   Timing of Epithelization: 
First 24 Hrs of injury :-Changes in the epidermis leading to re-
epithelization begin within 24 hours of the formation of a cutaneous 
wound.
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•   MECHANISMS OF WOUND HEALING : 
Wound healing is a complex process of inflammation, proliferation, angiogenesis 
,collagen maturation and wound contraction. 
•   TYPES OF WOUND HEALING : 
     Primary union – It is the healing of clean wounds with limited epithelial 
loss.ex-surgical incisions. 
    Secondary healing : 
There is large component of tissue destruction, healing takes place by 
inflammation and wound contraction. 
Growth factors: 
Growth factors are secreted proteins from many tissues in the body exert varied    
effects on cell function. Growth factors stimulate or inhibit progression through the 
cell cycle that Control cell viability or death, or that act principally to regulate cell 
differentiation. 
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Their modes of action include Autocrine, Paracrine, juxtacrine, intracrine   modes. 
Paracrine mode of action occurs when a growth factor that is secreted by one cell has an 
effect on adjacent cells. juxtacrine is similar as  paracrine, although the growth factor is 
bound to the cell membrane or   extra cellular matrix. Autocrine   actions are mediated 
by a growth factor on its cell of origin after its secretion in to the extracellular 
environment. Intracrine actions occur inside the cell of origin. The effects of GF are 
mediated by activation of specific receptors. These receptors are transmembrane proteins. 
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                                  Various  Growth factors comparison
21,22 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
      * EGF = epidermal growth factor; FGF = fibroblast growth factor; GMCSF =granulocyte-
macrophage colony-stimulating factor; HGH = human growth hormone; IL-1= interleukin-1; IGF-1 = 
insuling growth factor-1; PDGF = platelet-derived growth factor; TGF-ß = transforming growth factor-ß 
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PDGF21 
It was discovered as a protein released from the alpha  granules of platelets. 
It was purified from platelets as a highly basic 30- kilo delton dimeric protein. 
Purified   PDGF was found to consist of two related   chains, PDGF-  A,  PDGF-B,  
products  of  separate  genes.  
 
 PDGF  binds to receptors like PDGFR-α,PDGFR-β.They  also are related in 
structure and sequence but are distinct gene products. 
 
 Both growth factors  and their receptors are expressed in a wide variety of  
cell and tissue types. PDGF-BB  has  been  prepared and purified  for use   in   
clinical   studies   of   wound healing.  
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STRUCTURE OF PLATELET-DERIVED GROWTH 
FACTOR 
 
Mature PDGF-A  and -B chains are 109 amino acids in length and are 
60% identical.  All  three  combinations   of  growth  factor dimers  have  been  
isolated  from  tissues:  AA,  AB,  BB.In  addition  to  platelet,PDGF  has been  
isolated even from macrophage. Recently, two divergent members of the PDGF 
family were identified and termed PDGF-C and PDGF-D.
3 
 
PDGF RECEPTORS AND SIGNALING 
 
The two PDGFRs are ligand-activated  tyrosine protein kinases. The 
binding  of PDGF to the extracellular region of the receptor induces receptor 
dimerization. Both homo- and heterodimets  can form, depending on the ligand 
and the relative receptor abundance.   PDGFR-β   homodimers   bind   only   
PDGF   BB  and  DD;  PDGFR-α homodimers  bind PDGF AA, AB, BB, and 
CC; whereas  PDGFR-αβ  heterodimers bind PDGF BB, AB, CC, and DD.  
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Structure of PDGF receptors7 
 
 
 
 
BIOI.OGIC  EFFECTS 
PDGF action is essential for normal development.  One of the major 
actions of PDGF in the adult is in wound healing. Tissue injury leads to the rapid 
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release of abundant  PDGF  A  or  B  by  degranulating  platelets.  Other  short-
term  sources  of growth factor include activated macrophages  and endothelial 
cells. It is chemotactic for smooth muscle cells, fibroblasts, neutrophils, and 
monocytes and stimulates macrophage  activation.   
 
It is a potent  mitogen  for  fibroblasts  and  smooth  muscle cells  and 
stimulates  their  proliferation  in collaboration  with  other  growth  factors. PDGF  
induces  expression  of  fibronectin,  of  collagenase,  and  of  some  types  of 
remodelling  that occurs during wound healing. 
 
 
Various phase II and phase III studies showed effectively the efficacy, that is 
complete closure of the wound, and the reduction in the size of the wound. 
PDGF promote granulation tissue and stimulate cutaneous ulcer healing. It 
stimulates the proliferation of a variety of mesenchymal cells including fibroblasts. 
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DIABETES MELLITUS23,24,25
 
Definition : 
 
Diabetes mellitus is a cluster of metabolic diseases causing chronic 
hyperglycemia from defects in insulin secretion,action or both. . 
 
Classification 
TYPE I 
      Pathophysiology: 
I A      Autoimmune beta cell destruction  Insulin Deficiency 
I B      Develop insulin deficiency by unknown mechanism causing 
destructive process of beta cells  Lack immunologic markers 
 
Type II 
It is a heterogeneous group of disorders characterized by :- 
•   Impaired insulin secretion 
•    insulin resistance 
•   Increased blood glucose 
Type 2 DM is usually preceded by impaired glucose tolerance. 
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              Diagnosis  
 
The National Diabetic Organisation have fo rmulated  a  diagnostic criteria for 
DM-2 based on the following facts: 
 
• RBS ≥200 mgs / dL Or ≥11.1 m mol / L with symptoms of DM 
(Polyuria, Polydipsia, Weight loss) 
•   FBS ≥126 mgs / dL or ≥ 7.0 mmol / L 
 
• Strong  co-relation  b/w  ↑  FPG  &  ↑  HbA1c  concentration  but  currently  
not recommended for the diagnosis of DM. 
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Diagnosis of Diabetes Mellitus 
 
 
 
Terms 
 
Definition 
 
Random Blood Glucose 
 
(RBS) 
 
Blood Glucose levels without regard to time since 
last meal 
 
Fasting Blood Glucose 
 
(FBS) 
 
Blood Glucose levels when there is no caloric intake 
from past 8 Hrs 
 
 
35  
 
 
Neuropathy And Diabetes Mellitus  
 
• Diabetic neuropathy prevalence increases by age,peak period is 60yrs. 
    type1 & 2 DM. 
• May manifest as   Poly/Mono neuropathy or Autonomic Neuropathy 
 
   All nerve fibres are affected,since symptoms of diabetic neuropathy are similar 
to other types of neuropathy,various causes should be excluded. 
 
 
Poly-neuropathy / Mono-neuropathy
26,27,28
 : 
 
• The   most   common   form   of   diabetic   neuropathy   is   distal   
equivocal polyneuropathy. 
•   It presents as: 
1.  sensory loss - common presentation 
2.   Hyperesthesia 
3.   Paresthesia 
4.   Dysesthesia 
 
36  
• Symptoms includes a sensation of following, which begins in the feet 
& spreads proximally 
1.   Numbness 
2.   Tingling 
3.   Sharpness 
4.   Burning 
•   Physical examination reveals loss of sensation, ankle reflex loss and 
deranged position sense. 
 
treatment of diabetic neuropathy : 
 
•   Adequate glycaemic control  
• Vitamin B12 and folate supplementation 
•    Analgesics 
 
Lower Extremity Complications  
One of the major causes of morbidity in DM patients is foot ulcer and chronic 
infection. 
• The  causative factors are microvascular disease, deranged biomechanics 
of the foot, neuropathy and wound infection. 
 
37  
Neuropathy : 
It is the major cause of foot ulcers in diabetic patients with a prevalence 
of 80%. 
 
Motor and sensory neuropathy : 
Structural deformity of foot like claw toe,charcot joint occurs due to 
motor and sensory neuropathy. 
 
Peripheral sensory neuropathy : 
 
The normal foot biomechanics are lost resulting in trauma to the foot 
repeatedly. Often the patient is unaware of the trivial foot injuries. 
 
Autonomic neuropathy : 
Causes dryness of the foot resulting in fissures and ulcers. 
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VASCULAR CHANGES IN DIABETES
29 
 
Atherosclerosis:  It‟s a process of chronic accumulation of intraluminal 
plaque. 
 
 DM causes rapid development of atherosclerosis, Eventually atherosclerosis 
causes thrombosis of the vessel resulting in varied symptoms or dislodges as 
an  emboli.
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П. Endothelium: 
a. Nitric oxide, (NO): (EDRF-Endothelium derived 
relaxing factor)  
 
Nitric oxide, (NO) 
 
↑se Collagen synthesis           Regulates polyol pathway 
Changes in retinal 
circulation 
 
Accumulation in Kidney 
 
Nephropathy                              Neuropathy 
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b. Prostacyclin (PGI2) 
                                 Potent vasodilator  also inhibits,platelet  adhesion & 
aggression.Decreased in Diabetics & arterial wall of patients with old MI 
 
c. Thromboxane A2(TX-A2):>>>>Vasoconstrictor- Conteracts effect of 
N.O 
          decreased levels found in DM, HTN & hyperlipidemia. 
 
d. Endothelin::>>>>Vasoconstrictor  
          decreased levels found in DM around 3.5 times. 
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 Pathogenesis of diabetic ulcers. 
 
 
Diabetes 
Mellitus 
 
Neuropathy & limited joint 
mobility 
 
Atrophy of intrinsic muscles & clawing 
Pressure transfer from heel & toes to metatarsal heads 
 
No redistribution of 
pressure 
 
                                                        Ulceration 
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Predisposing factors for ulceration: 30 
 
1)  Limited joint mobility. 
 
2)  Peripheral neuropathy. 
 
3)  High plantar pressure. 
 
4)  Vascular diseases. 
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1. Biomechanics of diabetic foot 
 
Stance 
phase 
 
 
 
 
Contact phase              Mid-stance phase                Propulsive phase 
 
 
 
 
To toe off                     Opposite toe off     Active propulsion        Passive l 
opposite Limb              forefoot loading 
 
And heel 
lift 
 
 
 
 
Plantar flexion Dorsiflexion 
(max max 
Heel lift off    Opposite heel 
contact  
 
Pressure on 
 
supporting side 
& 
 
   & terminates 
with  
 
forefoot) 
 
ends with 
opposite 
 
supporting side 
  
 
side heel strike 
 
toe off 
 
 
 
Changes in foot caused by diabetes
31
 
1.   Peripheral neuropathy  
A.  Dryness of skin 
B.  Callus formation 
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2.   High pressure at bony prominences 
 
decreased plantar tissue 
thickness 
 
 
 
 
Weak intrinsic muscles of 
foot 
 
 
 
 
Imbalances of flexors & extensors causing clawing of foot 
 
 
 
 
Pulling away fat padding from metatarsal heads. 
 
 
3 Limited joint mobility  
  
Unknown etiology 
 
 
Collagen abnormality 
 
 
Thickening of skin tendons & joint capsules 
 
 
Decreased tissue flexibility 
 
 
Increased plantar pressure 
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4    Trauma  
 
Trauma 
 
 
 
 
Intrinsic                                                                           Extrinsic 
 
 
 
 
Repetitive stress from high pressure / Callus                            Ill-fitting 
footwear 
 
 
 
 
 
 
CLASSIFICATION OF DIABETIC FOOT ULCERS. 32 
 
 
There are various models which classify Diabetic ulcer. The Wagner 
classification is one such classification which is commonly used It 
classifies wounds by the extent of ulceration. 
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WAGNER CLASSIFICATION: 
 
Grade 1: Superficial Diabetic Ulcer 
Grade 2: Diabetic Ulcer Involving the fascia, ligament, joint capsule 
or tendon  
Grade 3: Deep ulcer with abscess or osteomyelitis 
Grade 4: Gangrene of the  forefoot 
Grade 5: Extensive gangrene of foot. 
 
The International Working Group on Diabetic Foot has proposed the 
PEDIS classification, which grades the wound in accordance to 
 
    •   Extent (area) 
    •   Sensation 
    •   Depth   
    •   Infection  
 Tissue Perfusion 
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WOUND DRESSING IN DIABETIC FOOT 
 
The management of wound and wound dressing is an important aspect of 
diabetic foot management. Proper dressing with cost effective dressing material, 
done with scientifically correct method can help in salvaging diabetic foot. The 
various functions of the dressings are: 
•   Isolation of the wound from external environment. 
•   Limit/reduce tissue oedema. 
•   Reduce pain. 
•   Improve gas exchange between tissues and blood. 
•   Limit inflammation. 
•   Absorb exudate. 
•   Should not promote bacterial growth. 
•   Prevent desiccation and contamination. 
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All the dressings can be classified as primary or secondary. Primary is the 
one, which covers the wound and is in direct approximity to the wound.While the 
Secondary dressing which holds the primary dressing in place is the secondary 
dressing. It has function of compression, occlusion and additional protection. 
 
VARIOUS TYPES OF DRESSINGS 
 
A wide variety of dressing solutions are available for dressing of infected 
diabetic foot ulcers. 
 
a. Eusol: contains bleaching powder and boric acid. Acts by chemical 
desloughing of the wound. 
b. Collagenase dressing: contains collagenase enzyme which helps in the      
break down of devitalized tissues. 
c. PDGF gel: contains the rh-growth factor Causing angiogenesis and  
formation of healthy granulation tissue. 
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d. Comupimet ointment: contains collagen crystals with Mupirocin and 
Metronidazole. Acts by enhancement of granulation tissue along with 
antibacterial action 
 
e. Aquacell: contains silver ions, which has anti-microbial action. Helps in 
cleansing the wound. 
 
f. Biological dressings: 
i. APLIGRAFT- Bioengineered skin  
ii. DERMA GRAFT- Human dermis 
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                                         MATERIALS AND METHODS 
 
Study design: Prospective  Randomized controlled trial. 
Source   of  Data : Patients  with  diabetic  foot  ulcers  admitted  in  surgery  
wards  at PSG Hospitals  over  a  period  from  august  2011 to august  2012 
 
Sample Size : 
50 patients 
25-patients -in the study group 
25-patients -in the control group 
Inclusion  criteria 
 1)    Age between 20 and 80 yrs. 
      2)     Diabetic ulcers located below the ankle. 
      3)     Diabetic ulcers of the leg-Grade 1 and 2(Wagner classification) 
      4)      Size  of  ulcer  less  than  10x10 cm[length X breath] 
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Exclusion  criteria: 
 
1)    Poor sugar control(HbA1c >12%) 
 
      2 )Patients with severe Anaemia(<7gm/dl)  
 
3)Diabetic ulcers grade 3,4 and 5(Wagner classification) 
. 
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Method 
 
The present study was carried out at  PSG Hospitals, Coimbatore, for a period of  
one year, where 50 patients with diabetic foot ulcers were included  in the present  
study. Using a pretested  and  predesigned  proforma    the study   population   was  
randomized   into  either  study  group  or  control  group  using an open label   
randomization technique. Out of  50,  patients, 25  took  treatment in  the form of 
conventional normal saline dressings and 25 took treatment with rh-PDGF dressing 
once a day.Glycaemic control  and  adequate  control  of infection was  maintained  in  
both  the groups. If  culture  grows  organism,  both control and  study  group  cases  
would  be  treated  with  antibiotics  as  per  culture  sensitivity report.X-ray foot was 
taken for all patients and bony involvement was excluded.The initial area measurement 
was taken on day 01 and final area measurement on day 15 was taken on transparent 
sheet. Plannimetry was used to measure the outcome that is the target ulcer area using a  
transparent  graph  sheet. Results were  calculated by  using  student  „t‟  test.  
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DRESSING TECHNIQUE 
For saline dressing. 
The ulcer was cleaned with normal saline and saline soaked gauze piece was 
kept over the ulcer which was covered with pad and roller bandage. 
 
For rh-PDGF dressing 
The infected ulcer was cleaned with Normal Saline. Commercially available  
rh-PDGF-BB gel (0.01%) was applied on the gauze piece and put on the ulcer. It was 
then covered with pad and roller bandage. 
 
The dressings were changed daily morning in both control and study group  for 15 days 
and appearance of healthy granulation tissue is observed. The initial area and final area  
of the size of the ulcer are measured on 15th  day by planimetry
33,34,35
 using a 
transparent graph sheet and subjected to statistical analysis. 
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The following formula was used to calculate % reduction in area of wound after 15 
days period in both cases and control groups. 
 
 
Rate of contraction of wound after 15 days of treatment = 
 
 
(Initial area – Final Area) 
                                                  X 100 
 
Initial are 
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                 OBSERVATIONS AND RESULTS 
                                               Age Distribution 
 
Age (Years) 
 
No. of Cases 
 
Percentage 
 
20-30 
 
02 
 
4% 
 
31-40 
 
06 
 
12% 
 
41-50 
 
11 
 
22% 
 
51-60 
 
19 
 
38% 
 
> 60 
 
12 
 
24% 
 
Total 
 
50 
 
100 
         
In our study it was observed that Diabetic foot was commonest in the age group 
between 51-60 yrs  of age. 
 
                     
20-30 31-40 41-50 51-60 > 60 Total
2 
6 
11 
19 
12 
50 
AGE(years) 
No. of Cases
56  
 
 
Sex Distribution 
 
Sex 
 
No of Cases 
 
Percentage 
 
Male 
 
34 
 
68.00% 
 
Female 
 
16 
 
32.00% 
 
Total 
 
50 
 
100. 
 
 
 
In our study in was observed that Diabetic foot was more common in the males 
(68.00%) as compared to females (32.00%). 
  
                    
0
5
10
15
20
25
30
35
40
45
50
Male Female Total
sex 
No of Cases 
57  
  
 Site of ulcer in the study 
 
 
Site 
 
No. of Cases 
 
Percentage 
 
Plantar 
 
28 
 
56.00% 
 
Dorsum 
 
22 
 
44.00% 
 
Total 
 
50 
 
100% 
 
 
 
 
In our study it was observed that diabetic foot more commonly occurs on 
the plantar aspect (56%) of the foot as compared to the dorsal aspect (44%). 
 
 
     
No. of Cases
0
20
40
60
Plantar
Dorsum
Total
A
xi
s 
Ti
tl
e
 
SITE 
58  
Onset of Diabetic Foot Ulcers 
 
Type of Onset 
 
No of Patients 
 
Percentage 
 
Traumatic 
 
32 
 
64.00% 
 
Spontaneous 
 
18 
 
36.00% 
 
Total 
 
50 
 
100 
 
 
 
Trauma is the most common cause of diabetic foot ulcer (64%) while only 
36%were spontaneous in origin. 
 
 
                  
 
 
Traumatic 
32 
Spontaneous 
18 
Total 
50 
No of Patients 
59  
 
 
 
Anti Diabetic Agents 
 
 
Anti Diabetic 
 
No. of cases 
 
Percentage 
 
OHA 
 
9 
 
18.00% 
 
Insulin 
 
41 
 
82.00% 
 
Total 
 
50 
 
100% 
 
 
 
    In our study most of the participants were taking Insulin for glycaemic control. 
 
 
 
0
10
20
30
40
50
60
OHA Insulin Total
No. of cases 
No. of cases
60  
         
 
Wound Contraction 
 
Group 
 
Mean  area 
reduction% 
 
S.D. 
 
Median 
 
P Value 
 
Control 
 
12.79% 
 
2.55 
 
       11.81 
 
 
Study 
 
38.55% 
 
2.52 
 
37.58 
 
P<0.001 
 
In our study it was observed that Mean % of area reduction was higher in study group 
(38.55%) as compared to the controls (12.79%). 
 
                        
Control
Study
12.79% 
38.55% 
Mean  area reduction% 
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 Diabetic foot ulcers in the study group had better mean % of wound contraction of 
38.55% as compared to the control group which had mean % 
of wound contraction of 12.79 %, the difference in the mean 
25.76% of area reduction of the two groups where studied using unpaired student t 
test was found to be significant (p<0.001). 
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Diabetic Foot ulcers(study group) treated with PDGF: 
 
 
 
BEFORE TREATMENT                                                AFTER TREATMENT 
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Diabetic Foot ulcers(study group) treated with PDGF: 
 
 
                                                    BEFORE TREATMENT    
                                             
             
                                                    AFTER TREATMENT                                                 
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                                             DISCUSSION          
                                                   
               Diabetic foot ulcers are chronic wounds, with prolonged  inflammation phase 
and shows cessation of epidermal growth. Invariably the diabetic foot ulcers are  
resistant to heal because of multidrug resistant organism growth and microvascular 
complications. 
 
The  present  study  was  conducted  at  PSG hospital,coimbatore to study the effect of 
use of PDGF in diabetic foot ulcers.In the present study it was seen that the incidence 
of diabetic foot ulcers were more in males (68%) as compared to females (32%). The 
second national data source, NHDS documented more males suffering from diabetic 
foot ulcer than females.  
 
Diabetic foot ulcers are most commonly seen in 5th decade (38%), the next common 
being in the sixth decade .While only 22% of the patients were in the fourth 
decade.Older the patient more the prevalence of  having diabetic foot ulcer. In this study 
patients with vascular complications such as pulse less limb and the patients with 
osteomyelitis were excluded.  
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In this study, 64% of the ulcers were traumatic in origin, trauma being the 
triggering factor secondary to neuropathy. 36% were spontaneous in origin 
secondary to blister rupture or unnoticed trivial trauma. 
 
More than half (56%) of the patients had ulcer on the plantar surface of the 
forefoot and the remaining (44%) had on the dorsum of foot. Study conducted by 
Edmonds et al. (Edmonds)
36
 showed more foot ulcers were on plantar and fore foot 
areas. Most of the diabetic foot ulcers are invariably due to poor foot care and due to 
gait abnormalities.  
 
Most of the patients (82%) were on insulin for control of sugar  
whereas only 18 % were on Oral Hypoglycaemic Agents.In our study it was observed 
that participants receiving rh-PDGF dressing had better wound contraction of 38.55.As 
compared to the group receiving only conventional dressing (normal saline dressing) in 
whom the mean wound contraction was 12.79% these were found to be statistically 
significant on unpaired Student t test (p<0.001) suggesting that rh-PDGF  dressing  
enhances wound healing in diabetic wounds. 
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We have found 12.79% (S.D; 2.55: Median; 11.81) contraction of wounds in 
the control groups as compared to 38.55% (S.D; 2.52, Median; 37.58) contraction of 
wounds in study group.  Therefore,  study  groups  are  having 25.76 %  more  
wound  contraction  as compared  to  control  group.  On applying unpaired 
student t test p<0.001 which is Statistically significant. From our study, we 
can say that rh-PDGF dressing therapy facilitates wound healing in patients 
suffering from diabetes mellitus. 
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                                                   CONCLUSION 
 
 
 
The wounds in the study group treated with rh-PDGF dressing contracted 
more than the wounds in the control group (38.55% Vs. 12.79%; P = < 0.001- 
Statistically Significant) which indicates rh-PDGF dressing  is an effective 
modality to facilitate wound contraction in patients suffering from diabetes. Rh-
PDGF dressing is found to be more effective, safe promoter of wound healing and 
can be used as an adjunct to saline dressings for healing of diabetic wounds. 
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PROFORMA 
 
 
I) PATIENT IDENTIFICATION DATA: 
 
NAME                                                  IP/OPD NO 
AGE                                                     SEX                                                      
            DOA:                                                       OCCUPATION: 
DOD:                                               
ADDRESS 
 
II) CHIEF COMPLAINTS: 
MEDICAL HISTORY: 
Peripheral Neuropathy:      
Nephropathy          
Retinopathy 
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Retinopathy 
 
 
PVD 
 
 
CVD 
 
 
DIABETIC STATUS: 
TYPE: 
DURATION: 
MEDICATION:                              Oral Hypoglycemic          Insulin 
 
(         )                           (     )    
COMPLICATION    Neuropathy        (         ) 
 
                                                   Vasculopathy      (         ) 
 
            ULCER DETAIL : 
1. Mode of onset 
                                                Traumatic                (         ) 
Spontaneous      (         )       
Pressure      (         )  
Others                         (         )         
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2. Duration 
3. Progress 
 
WOUND OBSERVATION: 
                   1.   Site 
2.   Size 
3.   Shape 
4.   Edge 
5.   Margin 
6.   Floor 
7.   Base 
8.   Discharge 
9.   Surrounding Skin 
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NERUROLOGICAL EXAMINATION  : 
VASCULAR EXAMINATION                                          
                                                                Right         Left                                              
 
             Popliteal artery                                                                                      
            Ant . Tibial artery 
             Post tibial artery 
             Dorsalis pedis  artery                                                                      
                                    
78  
INVESTIGATIONS. 
CBC 
FBS   
Hba1c     
Sr. Creatinine 
UKB 
Urine : Routine 
Microscopy 
X-ray Foot 
AP View 
Lat. View 
Wound C/s 
WOUND AREA MEASUREMENT ON D1 in cm
2 
Type of Dressing –        saline  dressing                           (           ) 
 
-             rh-PDGF  dressing                      (          ) 
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MASTER CHART-STUDY GROUP 
 
 
 
 
Sl. 
no 
 
 
Ip.no 
 
Age 
& sex 
 
 
0nset 
 
 
Site 
 
Anti 
DM 
Rx 
 
Initial Area 
in mm2 
 
Final Area 
in mm2 
 
IA-FA= CA 
 
%Area 
Reduct- ion 
1  
I11019046 
 
50/M 
 
T 
 
P 
 
I 
 
1321.8738219.
003 
 
219.643 
 
1102.234 
 
38.65 
2  
I11019267 
 
40/M 
 
T 
 
D 
 
O 
 
3181.937 
 
2060.9639 
 
1120.9740 
 
34.23 
3  
I11020569 
 
46/F 
 
S 
 
P 
 
I 
 
3563.038 
 
2110.0311 
 
1453.0060 
 
41.78 
4  
I11021373 
 
46/F 
 
T 
 
D 
 
O 
 
1783.993 
 
1090.5549 
 
693.4390 
 
37.87 
5  
I11019634 
 
60/M 
 
S 
 
D 
 
I 
 
2735.654 
 
1656.4385 
 
1097.2150 
 
38.45 
6  
I11019336 
 
55/M 
 
T 
 
P 
 
I 
 
1563.836 
 
942.3675 
 
621.4690 
 
38.74 
7  
I11017586 
 
50/F 
 
T 
 
D 
 
O 
 
2536.974 
 
1625.6929 
 
911.2811 
 
34.92 
8 I11018576 51/M T P I 1535.736 890.2661 645.4699 41.03 
9  
I11019934 
 
70/F 
 
T 
 
P 
 
O 
 
1432.388 
 
881.6348 
 
550.7532 
 
37.45 
10  
I11016797 
 
56/M 
 
S 
 
D 
 
I 
 
2536.84 
 
1592.3745 
 
944.4700 
 
36.23 
11  
I11019697 
 
64/M 
 
T 
 
P 
 
O 
 
1535.736 
 
890.2661 
 
645.4699 
 
41.03 
12  
I11016558 
 
56/M 
 
T 
 
D 
 
I 
 
1432.388 
 
881.6348 
 
550.7532 
 
37.45 
13  
I11018576 
 
50/M 
 
S 
 
D 
 
O 
 
3231.937 
 
2010.9112 
 
1221.0260 
 
36.78 
14 I11017278  
70/F 
 
T 
 
P 
 
O 
 
2435.836 
 
1340.197 
 
1095.6390 
 
43.98 
15  
I11020382 
 
54/M 
 
T 
 
P 
 
I 
 
3216.073 
 
1729.2825 
 
1486.7900 
 
45.23 
16  
I11017802 
 
50/F 
 
T 
 
D 
 
I 
 
2433.947 
 
1498.0944 
 
935.8520 
 
37.45 
17  
I11017472 
 
60/M 
 
S 
 
P 
 
I 
 
2433.764 
 
1517.9386 
 
915.8250 
 
36.63 
18 
I11019021 75/M S D I 3546.836 2282.7436 1264.0920 34.64 
19 I11017700  
65/F 
 
T 
 
D 
 
I 
 
2435.635 
 
1393.6703 
 
1041.9600 
 
41.78 
20  
I11021390 
 
29 /M 
 
T 
 
P 
 
I 
 
2194.937 
 
1241.0174 
 
953.9205 
 
42.46 
21  
I11017638 
 
30/M 
 
S 
 
P 
 
I 
 
3425.846 
 
1971.5744 
 
1454.2716 
 
40.45 
22  
I11019235 
 
74/M 
 
S 
 
P 
 
I 
 
3487.833 
 
2108.7438 
 
1379.0900 
 
37.54 
23  
I11020762 
 
51/M 
 
S 
 
D 
 
O 
 
2369.837 
 
1378.2972 
 
991.5398 
 
40.84 
24  
I11016307 
 
68/F 
 
T 
 
D 
 
I 
 
3598.937 
 
2273.4485 
 
1325.4885 
 
37.83 
25  
I11020795 
 
51/M 
 
T 
 
P 
 
I 
 
3563.038 
 
2110.0311 
 
1453.0060 
 
39.78 
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Sl 
No. 
 
 
I P No. 
 
 
Age/ 
Sex 
 
 
Onset 
 
 
Site 
 
Anti- 
DM Rx 
 
Initial 
Area 
mm2 
 
Final Area 
mm2 
 
 
IA - FA 
= CA 
 
% Area 
Reduct- ion 
1 I11021660 42/M T P O 3546.882 3186.164 360.718 11.17% 
2 I11020851 75/M T P I 3134.45 2845.141 289.309 10.23% 
3 I11023046 55/M S P I 2673.993 2360.066 313.927 12.74% 
4 I11034652 38/F S D I 3547.273 3078.678 468.595 14.21% 
5 I11021390 69/M T P I 2534.45 2271.881 262.569 11.36% 
6 I11023570 38/M T D I 1344.994 1153.013 191.981 15.27% 
7 I11032995 40/M T P O 3564.98 3217.038 347.942 10.76% 
8 I11021801 55/M T P I 3365.45 2875.441 490.009 15.56% 
9 I11033103 65/M T P O 2673.83 2402.703 271.127 11.14% 
10 I11020569 67/F T D I 2893.003 2619.324 273.679 10.46% 
11 I11032726 68/M S D I 2663.748 2228.491 435.748 17.34% 
12 I11021373 69/F T P O 2513.734 2278.699 235.035 10.35% 
13 I11034765 38/F T P I 2436.748 2163.101 273.647 12.23% 
14 I11034156 60/M T P I 3226.56 2895.514 331.046 11.26% 
15 I11033177 70/F S P I 3456.643 3123.768 332.875 10.63% 
16 I11021623 46/M T D I 2263.744 1934.142 329.602 16.56% 
17 I11034271 52/M T P O 2673.83 2402.703 271.127 11.14% 
18 I11034998 45/F T P I 3428.923 2961.903 467.023 14.62% 
19 I11034925 41/F S D I 2283.485 1887.528 395.957 18.34% 
20 I11033920 60/M T P I 3546.875 3147.496 399.406 12.26% 
21 I11033995 45/M T D I 3317.992 2941.731 376.261 12.34% 
22 I11033621 67/F T P I 1945.644 1766.061 179.583 10.23% 
23 I11033920 51/M T D I 1925.773 1662.905 262.868 14.65% 
24 I11021795 40/M S D O 3187.093 2780.736 406.357 13.75% 
25 I11022775 66/M T D O 1672.934 1391.379 281.545 18.83% 
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